Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

This study has been completed.
Information provided by:
University of Oslo School of Pharmacy
ClinicalTrials.gov Identifier:
First received: April 27, 2006
Last updated: May 9, 2006
Last verified: April 2006
The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.

Condition Intervention Phase
Renal Transplant Recipients
Posttransplant Diabetes Mellitus
Posttransplant Impaired Glucose Tolerance
Drug: Nateglinide
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance

Resource links provided by NLM:

Further study details as provided by University of Oslo School of Pharmacy:

Primary Outcome Measures:
  • Glucose tolerance
  • Insuline release

Secondary Outcome Measures:
  • Glucose oxidation
  • Postprandial hyperlipidemia
  • Glomerular filtration rate
  • HbA1C
  • Fasting glucose
  • Plasma nitric oxide
  • Plasma endothelin-1

Estimated Enrollment: 15
Study Start Date: November 2002
Estimated Study Completion Date: November 2003

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Reduced glucose tolerance (fasting glucose < 6.1 mmol/L AND 2 hour glucose between 6.7 and 9.9 mmol/L) or posttransplant diabetes mellitus (fasting glucose > 6.1 mmol/L OR 2 hour glucose between >= 10.0 mmol/L)
  • Stable patients fgollowing renal transplantation, less than 25% variation in serum creatinine last week and serum creatinine < 200 micromol/L

Exclusion Criteria:

  • Patients with indulin dependent diabetes mellitus before or after transplantation
  • Planned change in daily prednisolone dose during the study period
  • Haemoglobin < 8g/dL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319189

Rikshospitalet, Section of Nephrology
Oslo, Norway, 0027
Sponsors and Collaborators
University of Oslo School of Pharmacy
Principal Investigator: Trond Jenssen, MD, PhD Rikshospitalet, Section of Nephrology
  More Information

ClinicalTrials.gov Identifier: NCT00319189     History of Changes
Other Study ID Numbers: Starlix in RTR 
Study First Received: April 27, 2006
Last Updated: May 9, 2006
Health Authority: Norway: Directorate of Health

Keywords provided by University of Oslo School of Pharmacy:

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 01, 2016